Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Vaillant JC, André T, Closset J, Salmon I, Emile JF, Van Laethem JL.
Bachet JB, et al. Among authors: paye f.
Ann Oncol. 2012 Sep;23(9):2327-2335. doi: 10.1093/annonc/mdr617. Epub 2012 Feb 29.
Ann Oncol. 2012.
PMID: 22377565
Free article.